Overview and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands								3 Months Ended	9 Months Ended	12 Months Ended
	Oct. 01, 2020	Sep. 29, 2020 USD ($) shares	Sep. 10, 2020	Aug. 24, 2020 USD ($) shares	Jul. 21, 2020 USD ($) shares	Jul. 13, 2020 USD ($) shares	Jul. 10, 2020 $ / shares shares	Sep. 30, 2020 USD ($) shares	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) $ / shares shares	Aug. 20, 2020
Overview And Basis Of Presentation [Line Items]
Distribution, record date	Sep. 22, 2020
Stockholders' equity, reverse stock split			one-for-nine reverse stock split
Stockholders' equity, reverse stock split, ratio			0.111111111
Accumulated deficit										$ (57,993)	$ (73,692)
Common stock, par value | $ / shares							$ 0.01			$ 0.01	$ 0.01
Common stock, shares authorized | shares							150,000,000			150,000,000	150,000,000
Extinguishment of debt						$ 32,600
Impact from recapitalization transactions						69,879		$ 69,879
Gain on extinguishment										$ 2,691
Additional capital contribution, shares | shares		9,000			740,000
Capital contribution from PDL		$ 97			$ 8,000				$ 20,666
Financial Support, Capital Contributions
Overview And Basis Of Presentation [Line Items]
Additional capital contribution, shares | shares				747,000
Capital contribution from PDL				$ 29,000
Issuance of common stock				8,334
Stock issued during period, remaining cash contribution amount				$ 20,666
Common Stock
Overview And Basis Of Presentation [Line Items]
Impact from recapitalization transactions, Shares | shares								6,221,000
Fair value of debt						$ 67,188
Impact from recapitalization transactions								$ 62
Additional capital contribution, shares | shares								1,847,000
Issuance of common stock								$ 18
Series A Preferred Stock
Overview And Basis Of Presentation [Line Items]
Number of shares exchanged | shares							30,000
PDL BioPharma, Inc
Overview And Basis Of Presentation [Line Items]
Shares distribution ratio to PDL shareholders	7.5879%
Shares issued in exchange for extinguishment of Preferred stock | shares							3,415,000
PDL BioPharma, Inc | Common Stock
Overview And Basis Of Presentation [Line Items]
Common stock shares issued in exchange for extinguishment of debt | shares						2,806,000
Impact from recapitalization transactions, Shares | shares						6,221,000
PDL BioPharma, Inc | LENSAR
Overview And Basis Of Presentation [Line Items]
Percentage of common stock owned								81.50%	81.50%
PDL BioPharma, Inc | PDLIH
Overview And Basis Of Presentation [Line Items]
Distribution of ownership interest in its wholly owned subsidiary												100.00%